Back to School: How biopharma can reboot drug development. Access exclusive analysis here
LGND's Seragen Inc. subsidiary (Hopkinton, Mass.) sold to Pharmaceutical Partners its royalty rights to Zenapax daclizumab
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury